TL;DR
This study uses a multi-pronged approach, including Mendelian randomization and multi-omics analyses, to identify plasma metabolites that causally influence breast cancer risk. They pinpoint SPP1, a protein highly expressed in macrophages, as a key player that promotes cancer cell proliferation and migration, suggesting it as a promising therapeutic target.
What Problem Does This Paper Address?
Breast cancer is a major global health concern, and while metabolic reprogramming is known to occur, the specific causal links between plasma metabolites and breast cancer risk remain unclear. Existing studies are often limited by small sample sizes or confounding factors. This research aims to establish these causal relationships more rigorously and to uncover the underlying molecular mechanisms, ultimately seeking to identify new therapeutic targets for personalized treatment.
Methods
The researchers employed a sophisticated analytical pipeline:
- Mendelian Randomization (MR): This statistical approach uses genetic variants as instrumental variables to infer causal relationships between exposures (plasma metabolites) and outcomes (breast cancer). They used multiple MR methods (Inverse Variance Weighted, MR-Egger, Weighted Median) and sensitivity analyses (Cochran's Q test, MR-PRESSO, leave-one-out) to ensure robustness and check for pleiotropy.
- Linkage Disequilibrium Score (LDSC) Regression: Used to assess genetic correlations between plasma metabolites and breast cancer, helping to identify potential shared genetic underpinnings.
- Summary Mendelian Randomization (SMR) Analysis: Combined genetic instruments with expression quantitative trait loci (eQTL) data to map genetic variants to genes, identifying potential molecular mechanisms.
- Bulk RNA Sequencing: Analyzed gene expression in breast cancer tissues versus healthy tissues to identify upregulated genes.
- Single-Cell RNA (scRNA) Sequencing: Investigated the immune cell landscape and the expression patterns of key genes within different immune cell types in breast cancer.
- Immunohistochemistry and Multi-fluorescence Staining: Validated the expression of key proteins (like SPP1) in clinical tissue samples.
- In Vitro Assays: Used cell culture models (MDA-MB-231 breast cancer cells and THP-1 macrophages) to experimentally test the functional impact of SPP1 on cancer cell proliferation, migration, and invasion, and to investigate the effect of myristic acid on SPP1 expression.
- Candidate Drug Prediction: Utilized databases to identify potential drugs that could target identified genes.
- PheWAS (Phenome-Wide Association Study): Explored potential side effects or unrecognized horizontal pleiotropy associated with SPP1.
Datasets
- GWAS Summary Statistics:
- 1091 plasma metabolites and 309 metabolite ratios from the Canadian Longitudinal Study on Aging (CLSA) cohort (n=8299).
- Breast cancer data from the Breast Cancer Association Consortium (BCAC) (n=228,951, including 122,977 cases and 105,974 controls).
- eQTL Data: From the eQTLGen consortium (peripheral blood expression data from 31,684 individuals).
- Bulk RNA-Seq Data:
- GSE42568 dataset (121 samples: 104 breast cancer, 17 normal).
- External validation cohorts: GSE29431 and GSE57297.
- scRNA-Seq Data:
- GSE195861 (breast cancer immune landscape).
- External validation cohorts: GSE148673 and GSE161529.
- Clinical Samples: Nine breast cancer samples from patients undergoing surgery.
- Drug Signatures Database (DSigDB): Used for candidate drug prediction.
- UK Biobank: Used for pheWAS analysis (15,500 binary and 1500 continuous phenotypes).
Key Insights and Ideas
- Metabolites as Causal Drivers: The study moves beyond correlation to establish that certain plasma metabolites causally influence breast cancer risk, not just reflect it. This is a crucial step for developing targeted interventions.
- SPP1: A Key Player in the Tumor Microenvironment: The identification of SPP1 (Osteopontin) as a central molecule is significant. Its high expression in macrophages, and its ability to promote cancer cell proliferation and migration, highlights the critical role of the tumor microenvironment in cancer progression.
- Myristic Acid's Regulatory Role: The finding that myristic acid, a plasma metabolite, directly upregulates SPP1 expression in macrophages provides a concrete link between a circulating metabolite and a key pro-cancer protein. This opens avenues for dietary or metabolic interventions.
- Multi-omics Synergy: The integration of GWAS, eQTL, bulk RNA-seq, and scRNA-seq data was essential for not only identifying candidate metabolites but also for unraveling the molecular pathways and cellular players involved.
Key Results
- Seven significant plasma metabolites were identified with reliable causal effects on breast cancer risk.
- Six metabolites were predicted to increase breast cancer risk, including cysteinylglycine disulfide, docosadienoate (22:2n6), histidine to pyruvate ratio, and myristoleate (14:1n5).
- Two metabolites were predicted to reduce breast cancer risk: 3-bromo-5-chloro-2,6-dihydroxybenzoic acid and caffeine to paraxanthine ratio.
- SPP1 and ADM2 were identified as the two key PMRGs upregulated in breast cancer tissue.
- SPP1 expression was significantly higher in breast cancer tissue in external validation cohorts.
- SPP1 was primarily localized to monocytes/macrophages in scRNA analysis and confirmed by immunohistochemistry.
- Macrophage SPP1 knockdown suppressed breast cancer cell proliferation and migration, while SPP1 overexpression promoted these malignant phenotypes.
- Myristoleate upregulated SPP1 expression in macrophages in a dose-dependent manner.
- Top 10 candidate drugs predicted to downregulate SPP1 were identified, including ketoconazole and progesterone.
Limitations and Future Work
- Relaxed GWAS Threshold: The study used a relaxed significance threshold for GWAS (P < 1e-05), which could increase the possibility of false positives. The authors acknowledge this and mention using FDR control to mitigate it.
- Subset of Metabolites: Only a subset of significant plasma metabolites was included in subsequent analyses, potentially leading to the exclusion of valuable information.
- European Ancestry Bias: The GWAS data were primarily from individuals of European ancestry, limiting the generalizability of the findings to other populations.
- Suggestive Metabolites: The authors suggest mapping genetic instruments for "suggestive" plasma metabolites to facilitate further analysis.
- Broader Ancestry Studies: They emphasize the need for extensive GWAS analyses of plasma metabolites in other ancestries to ensure generalizability.
- Further Exploration of SPP1 Regulation: While myristoleate was identified as a regulator, further exploration of upstream regulatory factors of SPP1, including other plasma metabolites, is needed.
- Clinical Translation: The identified candidate targets and drugs require further validation and clinical investigation.
Summary updated